Midostaurin
About
Therapy type: Targeted therapy
Therapy strategy: FLT3 inhibition
Mappings
NCI Thesaurus: Midostaurin (coding:ncit:C1872)
RxNorm: midostaurin (coding:rxcui:1919083, coding:omop:1594003)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835Y | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835A | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835E | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835H | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835N | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835S | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.D835V | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | FLT3 p.I836del | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| FDA (2) | CDK12 oncogenic variants | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin |